The 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30-February 2, 2000
Jules Levin, NATAP

* Selected Highlights and Reports from Leading Researchers, 
* In-Depth Discussion of Conference Information on NATAP WOR Radio Show with leading HIV Researchers 

NATAP will bring you daily highlights through our email distribution program and will post the highlights to our web site. This year reporting will be provided as usual by Jules Levin, but for the first time reporting will be expanded to include selected leading researchers. These researchers will provide some daily highlights but will also provide end-of-conference summaries and take home messages. As well, NATAP has a radio show on WOR 710 AM in New York City every Sunday from 11pm to 12 Midnight. Immediately following this Conference, leading thought leaders and HIV researchers will guest on the radio show to discuss and explain new key information and their implications for use in treatment.

Information provided at key conferences such as these often are new findings and somewhat preliminary in nature. Some of the data from studies may be preliminary in terms of integrating it into practice by physicians. It's important to bear this in mind when reading and digesting the HRC reports.

The Conference starts 11am January 30th and ends Wednesday February 2nd at 4pm. The final session is the Late Breaker oral session which runs from 2-4pm. Often times key breaking information is reported at this session. This year interesting information and studies will be presented in the following areas, which NATAP expects to report on:

* therapy interruptions with and without therapeutic vaccines

* HCV & HBV- treatment issues in co-infection with HIV

* integrase inhibitors: pre-clinical research

* safety of discontinuing PCP prophylaxis

* resistance testing--genotypic and phenotypic

* issues in HIV for womwn

* pharmacokinetics of therapy in maternal/fetal and pediatrics ART therapy

* once daily regimens: indinavir/ritonavir; FTC+ddI+efavirenz

* new drugs: 

• T-20 and 2nd generation fusion inhibitor T-1249; future virus entry inhibitors; tipranavir (new protease inhibitor with potential in salvage situations);
• ABT-378 (new protease inhibitor that may have salvage utility) 72 week update in treatment-naives and 48-week data in PI-experienced & NNRTI naive; 
• BMS-232632 (new once-daily protease inhibitor)- first-time data from human studies; 
• initial human data on DAPD- new NRTI (may be effective for salvage);
• AG1549- new NNRTI that may be useful in salvage